MRSA in People Who Inject Drugs: Estimating burden and risk factors Dr Maya Gobin – Consultant Epidemiologist.

Slides:



Advertisements
Similar presentations
Meeting need and improving coverage workshop. Meeting need: calculating and improving coverage.
Advertisements

Endemic or Outbreak? Differentiating recent transmission of an historic tuberculosis strain in New York City IUATLD-NAR 16 th Annual Meeting February 23-25,
HIV Self-Sampling: Establishing a sustainable service
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
Syphilis and HIV screening initiatives in North Carolina jails Lynne A. Sampson PhD, MPH HIV/STD Update September 25, 2008.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
Sex work among people who inject drugs in England, Wales & Northern Ireland: Findings from a National Survey of Health Harms and Behaviours Sara Croxford,
Tuberculosis in the UK 2013 report
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
Fidelma Fitzpatrick Consultant Microbiologist, Health Protection Surveillance Centre & Beaumont Hospital, Dublin, Ireland HPSC, SARI and National HCAI.
Infection Control- Issues in the Community Dr Yimmy Chow Interim Director and Consultant in Communicable Disease Control NW London Health Protection Team,
All Change! Infections, injecting drug use and harm reduction. Vivian Hope IDU Team, HIV & STI Department, Health Protection Services – Colindale Dr Vivian.
SOHO RAPID ACCESS CLINIC. AIMS: n To provide a client focussed, low threshold flexible prescribing service. n To offer an easily accessible assessment.
Salford’s Alcohol Strategy Background Salford’s Drug and Alcohol Strategy Safe. Sensible. Social. : next steps in the national alcohol.
Cleanliness Champions: Evaluation of impact on HAI in NHSScotland Professor Jacqui Reilly HPS.
Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS
The role of the English Surveillance Programme on Antimicrobial Use & Resistance in improving stewardship Susan Hopkins Consultant Infectious Diseases.
Mental Health Commissioning in Tower Hamlets 15 th October 2015.
22 February 2016 GRASP (Gonococcal Resistance to Antimicrobials Surveillance Programme) Catherine Ison Sexually Transmitted Bacteria Reference Laboratory.
GENOMICS TO COMBAT RESISTANCE AGAINST ANTIBIOTICS IN COMMUNITY-ACQUIRED LRTI IN EUROPE (GRACE) H. Goossens (Coordinator), K. Loens (Manager), M. Ieven.
Sexual Health: where we are now and our vision for the future Dr. Mayada Abu Affan.
South West Hepatitis C Needs Assessment Dr Maya Gobin Health Protection Services (South West)
Harm from Invasive Devices Dr. Eleri Davies, Faculty Lead HCAI.
Point of Care Diagnostics for Hospital Acquired Infections (HAIs): Health Economics Perspective Detection & Identification of Infectious Agents (DIIA)
Carriage Rates of Methicillin-Resistant Staphylococcus aureus (MRSA) Among College Students Ryan Kitzinger, Leigh Nelson, Chad Sethman, Ph.D. ABSTRACT.
Thematic Priorities for ATF Applications Presentation by Secretariat of Council for the AIDS Trust Fund in Briefing Session on 27 July
Sexual Health Improvement for Populations and Patients (SHIPP) John Macleod, Thara Raj, Annette Billing 17 th June 2016 #BHPhitconf.
Addiction Health Integration Team- ADDHIT Richard Chidwick, Leonie Roberts, Jo Kesten, Maya Gobin, Matt Hickman, Katherine Williams.
Section 1: Introduction Dr Somen Banerjee, Director of Public Health London Borough Tower Hamlets.
South East London Homeless Health Needs Audit
Dr. Mohammed Omar Khalifa
Helen Green Public Health Registrar (ST3) West Midlands
Enabling the use of information locally
PHE data sources for STI & HIV
The epidemiology of IPED users attending IEP services in Scotland
Antibiotic Resistance
SITES & COORDINATING CENTRES
Outbreak Investigations
Table 1 Demographic and clinical characteristics of 758 admitted patients for whom cultures of nares were performed to assess methicillin-resistant Staphylococcus.
Welcome Dr. Eleri Davies, Faculty Lead HCAI.
Amanda D. Castel, MD, MPH Assistant Research Professor
Cascade of care for persons newly diagnosed
Sherry Deren, Sung-Yeon Kang, Milton Mino & Honoria Guarino
International Union against Sexually Transmitted Infections
Maternal health and early years
MODULE 2- EPIDEMIOLOGY OF DRUG USE IN THE AMERICAS
Hepatitis B and C management pathways in prison:
ECDC-EMEA Joint Technical Report Part I: Trends and burden of antimicrobial resistance in the European Union Zsuzsanna Jakab, Director European Centre.
Local Tobacco Control Profiles The webinar will start at 1pm
Cost utility of alternative Carbapenemase
New epidemiology of Staphylococcus aureus infection in Asia
22 November 2018 Factors predicting usage of low dead space syringes and association with Hepatitis C prevalence amongst people who inject drugs in the.
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
Neonatal sepsis in Kilifi
Hepatitis E in Ireland Dr Joanne O’Gorman & Niamh Murphy
STIs among people who use drugs
Health Protection Surveillance Centre
Blood borne viral hepatitis action in Wales
To Dip Or Not To Dip – Improving the management of Urinary Tract Infection in older people Improving Patient Safety & Care 6th Feb 2019 Continuous Learning,
Epidemiology of Colorectal Cancer in England: is it changing?
Population structure analyses of Staphylococcus aureus at Tygerberg Hospital, South Africa, reveals a diverse population, a high prevalence of Panton–Valentine.
Ambitions and Trajectories
Integrating Hepatitis C care for at-risk groups: Findings from a Multi-centre Observational Study in Primary and Community Care Nic An Riogh E1, Swan D¹,
Using Whole Genome Sequencing Analysis in California
G.M. Rossolini, E. Mantengoli  Clinical Microbiology and Infection 
Consultant Clinical Biochemist
Unplanned Care Workstream Emerging plans for 2019/20 CCF, July 2018
Introduction to epidemiology
Illustrative Cluster Detection and Response Strategy
Sexually transmitted infections – trends and challenges
Presentation transcript:

MRSA in People Who Inject Drugs: Estimating burden and risk factors Dr Maya Gobin – Consultant Epidemiologist

MRSA: the original “superbug” 2MRSA in PWID

We all know what MRSA is… Methicillin Resistant Staphylococcus Aureus Community-acquired MRSA (C-MRSA) identified over 20 years ago Costly:  Hospital admission (£4949)  Lower limb amputation (£18K)  Hospital fines (£44K for each infection exceeding agreed limit)  Potential for C-MRSA to develop more virulent strain – impact for general population 3MRSA in PWID in Bristol, South West England

MRSA activity in England 4MRSA in PWID

MRSA activity in England 5MRSA in PWID

Intravenous drug use (IVDU) is a known risk factor for MRSA colonisation. MRSA infection in People who inject drugs (PWID) previously reported in North America, Liverpool, London and Brighton. Burden of MRSA amongst PWID not known Risk factors for MRSA colonisation and infection in PWID are not fully understood. - Age - Sex - Injecting drug habits (use of crack-cocaine, frequency and site of injections and reuse of needles/syringes) 6MRSA in PWID

About PWIDs in Bristol: 5,349 Opiate & Crack Cocaine users (2011/12) 4 th highest prevalence of Opiate Use in England 2 nd highest prevalence Crack use Highest prevalence of people using both Heroin & Crack 1,499 -2,700 estimated injectors ‘Snowballing’ - Heroin and Crack injected together & frequently Most frequently used injection site – femoral vein (groin) 7MRSA in PWID in Bristol, South West England

MRSA in PWID: Bristol situation Post Infection Review (PIR) introduced nationally in 2013 to identify possible causes/risk factors for MRSA bacteraemia. An increase in MRSA bacteraemia reported amongst PWID noted in in in Cases predominantly groin injectors and homeless. Was this – 1.Better detection of an existing problem 2.Possible indicator of wider challenges of improving hygienic injecting a.The increase in street homeless people b.Poly drug used and disinhibited behaviour 3. Peculiarity of Bristol: PWID characteristics or MRSA strain type 8MRSA in PWID

Local investigation Aim: To estimate the burden of disease in PWID in Bristol To describe the characteristics of those with infection: including age, sex, housing, nature of drug use Method: Data linkage Lab and Bristol drugs services – 1 st April 2006 to 31 st January 2015 Collection of enhanced risk factor information as part of PIR process Review of activity in comparable cities 9MRSA in PWID

Burden of disease 10MRSA in PWID Annual number MRSA isolates in Bristol overall and amongst PWID 2006 to 2014, source BDP and UBHT

Clinical findings 11MRSA in PWID PWID accounted for 10.0% (129/1289) of all MRSA isolates, increasing from approximately 1.1% of the total reported in 2006 to 26.5% in Majority of PWID have MRSA isolated from skin and soft tissue sites In 2014, a third of PWID with MRSA isolated had the organism detected in blood. At least fourteen PWID had MRSA detected on two separate episodes between 2006 and 2014.

Demographic characteristics Age and sex distribution of cases Map of cases by post code of residence 12MRSA in PWID

Case review… 13 MRSA in PWID in Bristol, South West England PWID = 10.0% (129/1289) of all MRSA isolates, increasing from 1.1% of total reported in 2006 to 26.5% in , a third of PWID with MRSA isolated had the organism detected in blood. At least fourteen PWID had MRSA detected on two separate episodes between 2006 and Predominantly groin injectors; 50% homeless (50% not); 84 concurrent heroin and crack use. Cases across city – two ‘clusters’ Central & South History of DVT and OST were noted amongst the majority with PIR.

Summary Real and increasing problem - bacteraemia just the tip of the iceberg Likely to be under-estimating the true burden of disease in PWID Associated with poor health outcomes Reasons for the increase remain unclear 14MRSA in PWID

So why does MRSA appear ‘special and different’ in Bristol from early 2014? Hypotheses Reporting issue? (less likely since NHS England scrutiny?) Femoral vein most common site = least hygienic? (but common in many areas) Rapid growth of street homeless population ? (but from 2015) Injecting practise poor? (not unique) ‘Snowballing’ Pregabalin and synthetic cannabinoids = increased public disinhibited groin injecting Colonisation is so prevalent that risk of MRSA bacteraemia is very high? ‘Special & different’ MRSA clone – particularly resilient? 15MRSA in PWID in Bristol, South West England

Testing our hypotheses: Bristol’s response £ from Elizabeth Blackwell Fund to investigate: Prevalence and risk factors for MRSA infection amongst PWID Questionnaire –short version of UAM plus additional Qs -focus group with PWID June 2016: Bdp NSP staff trained to collect MRSA samples July – August 2016: incentivised screening PWID using Bdp NSP (city centre based and harm reduction truck in S Bristol) 16MRSA in PWID in Bristol, South West England

Testing our hypotheses: Bristol’s response Molecular epidemiology PHE Staphylococcus Reference Service analyse MRSA isolates (from 2006 & current screening) Whole Genome Sequencing (WGS) to: (i)Identify when MRSA acquired (ii)Describe transmission pathways (iii)Insights into genetic markers associated with antimicrobial resistance, virulence, fitness and transmissibility 17MRSA in PWID in Bristol, South West England

So why does MRSA appear ‘special and different’ in Bristol? Look out for the outcome of Bristol’s research in early MRSA in PWID in Bristol, South West England

Acknowledgements Bristol Drugs Project United Bristol Hospital Trust Bristol City Council Bristol CCG UoB 19MRSA in PWID